March 27th 2023
Here's some of what is coming soon to NeurologyLive® this week.
Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists
1.5 Credit / Neurology, Psychiatry
View More
Novel Treatment Approaches for Alzheimer Disease: Considerations for Pharmacists Across Care Settings
1.5 Credits / Neurology
View More
Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options
0.50 Credit / Neurology
View More
Novel Non-stimulant ADHD Treatments: A Review for Pharmacists
0.75 Credit / Neurology, Psychiatry
View More
Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs
0.75 Credit / Neurology
View More
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
View More
Strategies to Improve the Management of Migraine: Clinical Updates for Pharmacists and Patient-Case Review
1.0 Credit / Neurology
View More
Recognizing Rett Syndrome: Managed Care Insights on Disease Burden
1.5 Credits / Neurology, Rare Diseases
View More
Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term Extension
In participants who received placebo during the parent studies, rapid improvements were observed as early as week 1 after switching to zilucoplan, and continued through week 12 of the extension period.
Consensus Considerations Developed for SRP-9001 Adverse Event Management in DMD
The 12-person Dephi panel reviewed data from 3 clinical trials of delandistrogene maxeparvovec (SRP-9001; Sarepta), and developed considerations for the management of vomiting, myocarditis, acute liver injury, and immune-mediated myositis.
FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump
If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.
Post-Hoc Analysis of CHAMPION MG Study Highlights Ravulizumab’s Effects on Specific Muscle Domains
After previously showing positive effects on MG-ADL and QMG, ravulizumab continued to show improvements in ocular and respiratory muscle domains in myasthenia gravis.
A Balancing Challenge: Social Relationships in the Life of Adolescents With Narcolepsy
March 19th 2023Anne Marie Morse, DO, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, talked about the challenges that adolescents with narcolepsy face in their social relationships.
NeurologyLive® Brain Games: March 19, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Muscular Dystrophy Association (MDA).
FDA to Hold AdComm Meeting on Investigational DMD Treatment SRP-9001
The FDA has reversed course, deciding to hold an advisory committee meeting ahead of the May 29, 2023, action date for Sarepta’s investigational DMD agent SRP-9001 (also known as delandistrogene moxeparvovec).